Anne Lennard

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

Laurie H. Sehn, Neil Chua, Greg Dueck et al. · The Lancet Oncology · 2016 · 336 citations

Lymphoid Neoplasia, Oncology, Cancer Treatment +3

Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group

G.B. Ryan, Giovanni Martinelli, Marion Kuper‐Hommel et al. · Annals of Oncology · 2007 · 249 citations · Full text

Prognostic Factors, Lymphoid Neoplasia, Breast Oncology +4

Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation

Michal Sieniawski, Nithia Angamuthu, Kathryn Boyd et al. · Blood · 2010 · 227 citations · Full text

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study

Bruce D. Cheson, Neil Chua, Greg Dueck et al. · Journal of Clinical Oncology · 2018 · 162 citations · Full text